SAHPRA Section 21 explained — the SA medical cannabis pathway
How Section 21 works, what it authorises, how long it takes, and how Cannabuben fits into the regulatory chain.
Section 21 of the Medicines and Related Substances Act (101 of 1965) allows the South African Health Products Regulatory Authority (SAHPRA) to authorise the use of unregistered medicines for specific patients. Medical cannabis products aren't generally registered for sale in SA, so Section 21 is the legal path by which they reach patients.
How it works — the four-step path
- Clinical assessment. A HPCSA-registered practitioner reviews your case — symptoms, history, medications, and whether medical cannabis is clinically appropriate.
- Section 21 application. If the practitioner decides to prescribe, they file a Section 21 application to SAHPRA for each specific product.
- SAHPRA authorisation. SAHPRA reviews and authorises (typically 2–3 business days). Authorisation is patient-specific, product-specific, and valid for 6 months.
- Pharmacy dispensing. Once authorised, a licensed pharmacy dispenses the product and delivers it to you. Within the 6-month validity, repeats can be dispensed without a new application.
What Cannabuben does
When you order a Schedule 4, Schedule 6, or Section 21 medicine from our shop, the clinical-review step is built into the post-payment flow. A HPCSA-registered practitioner on our panel reviews the clinical screening you fill in, decides whether to prescribe, and if so files the Section 21 application on your behalf. You pay the consultation and SAHPRA fees upfront; medication and delivery are paid to the dispensing pharmacy.
If you prefer a dedicated telemedicine-consultation route instead of via a shop, Docto24 handles the same clinical path separately.
What Section 21 is not
- It's not a recreational or open-market legalisation.
- It's not a rubber stamp — SAHPRA can and does decline applications that don't meet the clinical threshold.
- It's not only for terminal conditions — common indications include chronic pain, insomnia, anxiety disorders, neuropathy, endometriosis, MS, epilepsy, and cancer-related symptom management.
- It's not separate from your medical aid — medical aid schemes generally don't cover Section 21 medicines, though some reimburse the clinical-review fee under code 0130.
Typical timeline
- Day 0: order placed, clinical screening submitted.
- Day 0–1: HPCSA practitioner reviews case.
- Day 1–3: if prescribed, Section 21 authorisation granted.
- Day 2–5: pharmacy dispenses and couriers.
- Day 3–7: product delivered.
Costs
Consultation fee (paid to the reviewing practitioner): R500. SAHPRA Section 21 fee: R400 per prescribed product. Medication and delivery: set by the dispensing pharmacy, paid directly to them. No Docto24 / Cannabuben mark-up on the medication itself.